mRNA technology has the potential to address diseases globally that have not had effective vaccines nor treatments to date. Read this report to learn about the promise of mRNA to prevent and treat endemic diseases in resource-limited areas with the populations who would benefit the most.
For nearly 20 years, the FHI Clinical project team has partnered with companies developing and deploying vaccines, treatments and preventive devices for malaria in 38 countries worldwide.
FHI Clinical has long-standing relationships, a local team and broad expertise in sub-Saharan Africa. We're ready to help you confidently expand your research across the region, finding the best-fit countries and populations for your target indication and study type.
FHI Clinical goes where our expertise is needed. Whether it requires working from a state-of-the-art facility or in a low-tech, rural setting, we provide services tailored to meet your study needs, from protocol design and site assessments to trial planning, implementation and management.
In this webinar, our panel of Africa-based researchers discuss the strong clinical research foundation, the community-centered approach and increasing regulatory harmonization in Africa. Watch to learn about the continent’s population diversity, expanding therapeutic area expertise and long-standing stakeholder engagement.
The Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) network was established through a partnership between local Liberian and international partners, including the U.S. National Institutes of Health, World Health Organization and FHI Clinical, to provide sustainable research infrastructure to address diseases of public health importance.
To address the urgency of vaccine development during a pandemic, innovative strategies are implemented across study design, regulatory processes, recruitment process and more. In this e-book, we describe some of those innovations and argue for incorporating these into the fabric of clinical trials — to establish a “new normal.”
The FHI Clinical project team supported site monitoring, site management and project management to assist the University of Notre Dame investigators achieve a level of rigor not typically required for a non-medical product in their double-blinded, randomized-cluster, placebo-controlled clinical trial of a spatial repellent against mosquitoes for malaria prevention.
In this webinar, industry veterans Michelle Berrey, MD, MPH, and Claudia Christian discuss the importance of quality data for a successful outbreak response plan.
Outbreaks large and small require rapid, coordinated responses. In this infographic, we describe eight considerations for outbreak responses, based on the collective experience of our experts.
FHI Clinical Headquarters
359 Blackwell Street, Suite 200
Durham, NC 27701 USA